CAD SPECTRAL Technologies logo CAD SPECTRAL Technologies

Smart Screening.
Zero Invasion.
Your eyes tell the story.

We are developing SPECTRA-Mini, a simple, non-invasive eye scan designed to help identify early risk of coronary artery disease and improve access to cardiovascular assessment.

🚧 Coming soon

The problem

Coronary artery disease is a leading cause of preventable death, yet it is often diagnosed late, especially in regional and remote communities with limited access to advanced cardiac testing.

Today’s pathways can involve multiple appointments, specialist referrals, and travel, creating delays and missed opportunities for early action.

The solution

SPECTRA-Mini uses advanced eye imaging and data-driven analysis to extract cardiovascular insights from the retina, enabling rapid screening without needles, radiation, or contrast agents.

Non-invasive
Fast & clinic-friendly
Designed for remote access
Data-driven risk insights
Clinical evidence (early): Our approach is being clinically validated against standard-of-care assessment pathways, with a focus on safety and real-world usability.
Concept illustration: eye vasculature connected to the heart

SPECTRA-Mini

A compact platform designed for primary care and community settings, bringing cardiovascular screening closer to where patients live.

Our innovation

SPECTRA-Mini device

Prototype concept image shown. Final design subject to iterative engineering and clinical feedback.

Designed for deployment

We’re optimising form factor, workflow, and portability to support screening in metro, regional, and remote environments.

Portable footprint
Simple workflow
Clinic-ready UI
Scalable deployment

Want updates? Email [email protected].

Why it matters

By shifting screening upstream, CAD SPECTRAL Technologies aims to reduce preventable heart attacks, improve health equity, and support earlier clinical decision-making.

Expert WA-Based Team

A multidisciplinary founding team combining cardiology, optical engineering, and clinical translation, based in Western Australia.

Dr Hadi Afsharan

Dr Hadi Afsharan

BSc, MSc, PhD

Co-Founder and CSO
  • Research Fellow, Harry Perkins Institute of Medical Research & The University of Western Australia
  • FHRI Translational Fellow; biomedical engineering and clinical translation expert
Associate Professor Barry Cense

Assoc. Professor Barry Cense

BSc, PhD

Co-Founder and CTO
  • Director, Optical and Biomedical Engineering Labs (OBEL), The University of Western Australia
  • PS-OCT expert; SPECTRA™ platform developer
Professor Girish Dwivedi

Professor Girish Dwivedi

MD, DM, MRCP, PhD, CCST (Cardiology), FESC, FASE, FRACP

Co-Founder and CMO
  • Wesfarmers Chair in Cardiology, Harry Perkins Institute of Medical Research & The University of Western Australia
  • Consultant Cardiologist, Fiona Stanley Hospital

About Us

A new way to see heart disease.

Heart disease often arrives quietly, with subtle signs that are easy to miss until it’s too late.

At CAD SPECTRAL Technologies, we believe early detection should be simple, accessible, and non-invasive: no needles, no radiation, and no long hospital journeys, just a quick eye scan.

The idea behind CAD SPECTRAL began with a simple insight: the eye is a window to the vascular system. Retinal features can reflect changes happening throughout the body, including the heart.

Why “CAD SPECTRAL”?

CAD stands for Coronary Artery Disease, and the initials of our founders: Cense, Afsharan, and Dwivedi.

Our journey

2023
Founding team formed around the shared goal of earlier, more accessible detection.
2024
Prototype development and clinical translation work advanced in Western Australia.
2025
Clinical validation activities underway, focused on usability and real-world deployment.
Now
Advancing SPECTRA-Mini toward scalable screening for primary care and community settings.

Behind every diagnosis is a person.
Behind every early detection is a life that could be saved.